| Dr Theodore J Ganley, MD | |
|
34th & Civic Center Blvd, Children's Hospital Of Philadelphia, Philadelphia, PA 19104-4306 | |
| (215) 590-1527 | |
| (215) 590-1501 |
| Full Name | Dr Theodore J Ganley |
|---|---|
| Gender | Male |
| Speciality | Orthopaedic Surgery |
| Location | 34th & Civic Center Blvd, Philadelphia, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023107117 | NPI | - | NPPES |
| 001648763 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | MD052070L (Pennsylvania) | Primary |
| Entity Name | Children's Surgical Associates Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326117185 PECOS PAC ID: 9739083494 Enrollment ID: O20040209000124 |
News Archive
In a speech on Wednesday, Secretary of State Hillary Rodham Clinton said that it is time to "elevate development as a central pillar of all that we do in our foreign policy," United Press International reports (1/6). According to Reuters,
A protein that plays an important regulatory role in heart failure in the heart also exerts powerful effects on the adrenal gland, Jefferson Medical College researchers have found. The protein, GRK2, is a potential drug target for heart failure.
Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. announced that following the regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use on April 25, 2013, the European Commission (EC) has granted the marketing authorization for XTANDI™ (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.
RegeneRx Biopharmaceuticals, Inc. announced today that it has been awarded a $3 million grant from the National Institutes of Health's National Heart, Lung and Blood Institute to support and accelerate the clinical development of its novel product candidate RGN-352, an injectable formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4, for patients who have suffered an acute myocardial infarction, or AMI, commonly known as a heart attack.
Deleting a gene in mouse embryos caused cardiac defects and early death, leading researchers to identify a mechanism that turns developmental genes off and on as an embryo matures, a team led by a scientist at The University of Texas M. D. Anderson Cancer Center reported today in Molecular Cell.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Theodore J Ganley, MD 100 E Penn Sq, The Wanamaker Building 9th Fl, Philadelphia, PA 19107-3323 Ph: (267) 425-9538 | Dr Theodore J Ganley, MD 34th & Civic Center Blvd, Children's Hospital Of Philadelphia, Philadelphia, PA 19104-4306 Ph: (215) 590-1527 |
News Archive
In a speech on Wednesday, Secretary of State Hillary Rodham Clinton said that it is time to "elevate development as a central pillar of all that we do in our foreign policy," United Press International reports (1/6). According to Reuters,
A protein that plays an important regulatory role in heart failure in the heart also exerts powerful effects on the adrenal gland, Jefferson Medical College researchers have found. The protein, GRK2, is a potential drug target for heart failure.
Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. announced that following the regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use on April 25, 2013, the European Commission (EC) has granted the marketing authorization for XTANDI™ (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.
RegeneRx Biopharmaceuticals, Inc. announced today that it has been awarded a $3 million grant from the National Institutes of Health's National Heart, Lung and Blood Institute to support and accelerate the clinical development of its novel product candidate RGN-352, an injectable formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4, for patients who have suffered an acute myocardial infarction, or AMI, commonly known as a heart attack.
Deleting a gene in mouse embryos caused cardiac defects and early death, leading researchers to identify a mechanism that turns developmental genes off and on as an embryo matures, a team led by a scientist at The University of Texas M. D. Anderson Cancer Center reported today in Molecular Cell.
› Verified 5 days ago
Samir Mehta, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3737 Market St, 7 Floor, Philadelphia, PA 19104 Phone: 215-662-3340 Fax: 215-222-8875 | |
Patrick John Cahill, MD Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 34th & Civic Center Blvd, Children's Hospital Of Philadelphia, Philadelphia, PA 19104 Phone: 215-590-1527 Fax: 215-590-1501 | |
Megan Elizabeth Gresh, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3601 A St, Philadelphia, PA 19134 Phone: 215-427-5000 | |
Nicolas Echeverria, MD Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 3401 N Broad St, Philadelphia, PA 19140 Phone: 215-707-2000 | |
Peter Francis Deluca, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 925 Chestnut St, Fl 5, Rothman Institute, Philadelphia, PA 19107 Phone: 267-339-3500 Fax: 215-503-0580 | |
Easwaran Balasubramanian, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3401 N Broad St, Philadelphia, PA 19140 Phone: 215-707-2111 Fax: 215-707-2324 |